Lanean...
Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
BACKGROUND: Although patients with EGFR mutated lung adenocarcinoma benefit greatly from tyrosine kinase inhibitors (TKIs), they inevitably develop acquired resistance after an average of 10–14 months of continuous treatment. METHODS: We retrospectively analyzed the clinical and histopathological da...
Gorde:
| Argitaratua izan da: | Thorac Cancer |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons Australia, Ltd
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5754316/ https://ncbi.nlm.nih.gov/pubmed/29120087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12549 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|